Sin conexión a internet: se muestra la versión guardada de la página.

Mesoblast Ltd

USUSD
← Al screener

Mesoblast Ltd (US:MEOBF) — Biotechnology: Biological Products (No Diagnostic Substances). Número de bolsas en las que cotizan las acciones de la empresa: 2. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.

Sobre la empresa

Sitio web
mesoblast.com
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sede central
MELBOURNE, VICTORIA, Australia
Consejero delegado
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Empleados
108
Acciones en circulación
1.3 mil M a 2026-06-30
Capital flotante
861.1 M
Capitalización bursátil
1.48 mil M USD
Insiders
36.28%
Inversores institucionales
17.44%
Industria (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
AU000000MSB8
Ratio de reparto
0%
FCF
−60.6 M USD
Deuda
127 M USD
caja neta
Racha de dividendos
—
Beneficios, FCF y dividendos pagados — para los 12 meses hasta 31.12.2025 (el último informe de la compañía).
Descripción

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Bolsas y tickers

BolsaTickerMonedaPrecioTipo
US USA StocksMEOBF OTCUSD1.39 +21.93%acciones ordinarias
AU Australian Securities ExchangeMSB principalAUD2 +3.36%acciones ordinarias

Precio en 3 meses

día alcista día bajista fecha ex-dividendo fecha de pagoPasa el cursor / toca un día — precios de apertura, cierre, máximo y mínimo

Dividendos

No se han encontrado pagos de dividendos (comprobado el 10.10.2026). Es probable que la empresa no reparta dividendos.

Noticias de esta semana

Aún no hay noticias del sitio web de la empresa.

anuncio

Principales accionistas

TitularParticipaciónAccionesFecha del informe
Itescu (Silviu) (Chief E…≈6.23%80.84 M2026-07-17
VANGUARD STAR FUNDS-Vang…1.05%13.66 M2026-04-30
VANGUARD TAX-MANAGED FUN…0.62%8.01 M2026-06-30
iShares Trust-iShares Co…0.53%6.88 M2026-07-31
Rose (Eric) (Director (N…≈0.52%6.75 M2026-01-09
DFA INVESTMENT TRUST CO-…0.36%4.68 M2026-04-30
VANGUARD Intl Eqy. INDEX…0.27%3.51 M2026-04-30
iShares Trust-iShares MS…0.24%3.07 M2026-07-31
SCHWAB STRATEGIC TRUST-S…0.15%1.99 M2026-05-31
Dimensional ETF Trust-Di…0.11%1.38 M2026-04-30
iShares Trust-iShares Co…0.09%1.23 M2026-07-31
SPDR INDEX SHARES Fd.S-S…0.09%1.19 M2026-08-31
Bell (Jane Catherine) (D…≈0.05%622 4922025-02-28
Burns (William) (Indepen…≈0.02%226 2502025-10-21
Legato Capital Managemen…0.01%47 3802022-06-30
Cobley (Lyn Elizabeth) (…≈0%63 0002026-01-09